I Redeker1,2, J Callhoff3, F Hoffmann4, J Saam5, H Haibel6, J Sieper6, A Zink3,7, D Poddubnyy6,3. 1. Medizinische Klinik für Gastroenterologie, Infektiologie und Rheumatologie, Charité - Universitätsmedizin Berlin, Hindenburgdamm 30, 12203, Berlin, Deutschland. imke.redeker@charite.de. 2. Programmbereich Epidemiologie, Deutsches Rheuma-Forschungszentrum, Charitéplatz 1, 10117, Berlin, Deutschland. imke.redeker@charite.de. 3. Programmbereich Epidemiologie, Deutsches Rheuma-Forschungszentrum, Charitéplatz 1, 10117, Berlin, Deutschland. 4. Department für Versorgungsforschung, Carl von Ossietzky Universität, Ammerländer Heerstr. 140, 26129, Oldenburg, Deutschland. 5. BARMER Institut für Gesundheitssystemforschung, BARMER Gesetzliche Krankenversicherung, Lichtscheider Str. 89, 42285, Wuppertal, Deutschland. 6. Medizinische Klinik für Gastroenterologie, Infektiologie und Rheumatologie, Charité - Universitätsmedizin Berlin, Hindenburgdamm 30, 12203, Berlin, Deutschland. 7. Medizinische Klinik mit Schwerpunkt Rheumatologie und Klinische Immunologie, Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Deutschland.
Abstract
BACKGROUND: Tumour necrosis factor-alpha inhibitors (TNFi) are an effective but expensive treatment option in axial spondylarthritis (axSpA) patients who fail to achieve disease control under conventional treatment. OBJECTIVE: The aim of this study was to assess the cost of illness in axSpA patients treated with and without TNFi. METHODS: Using German health insurance data, patients with axSpA who newly received TNFi between 2011 and 2015 were identified and matched by age and sex to a reference group of patients with axSpA without TNFi treatment. Costs for services performed in an outpatient setting, inpatient care, pharmacotherapy and for productivity loss due to absence from paid work were analyzed over a 2-year period. In patients treated with TNFi , the 2‑year period included 1 year before and 1 year after the initiation of TNFi. RESULTS: Data from 1455 axSpA patients who received TNFi treatment were included in the analyses. Costs for services performed in an outpatient setting, inpatient care, pharmacotherapy (excluding TNFi) as well as productivity loss significantly decreased after initiation of TNFi. Mean total costs increased from € 6075 in the year prior to TNFi initiation to € 27,871 in the year after TNFi initiation. Excluding costs for TNFi, total costs decreased by 22% to € 4761. Mean total costs among the reference group of 1455 age and sex-matched axSpA patients who did not receive TNFi remained stable over 2 years: € 3939 in the first year vs. € 3832 in the second year. CONCLUSION: Initiation of TNFi treatment led to a sharp increase in the total costs of axSpA patients. Part of this increase was offset by a decrease of costs for services performed in an outpatient setting, inpatient care, pharmacotherapy (excluding TNFi) as well as productivity loss. In patients who did not receive TNFi, the costs remained stable over 2 years.
BACKGROUND:Tumour necrosis factor-alpha inhibitors (TNFi) are an effective but expensive treatment option in axial spondylarthritis (axSpA) patients who fail to achieve disease control under conventional treatment. OBJECTIVE: The aim of this study was to assess the cost of illness in axSpA patients treated with and without TNFi. METHODS: Using German health insurance data, patients with axSpA who newly received TNFi between 2011 and 2015 were identified and matched by age and sex to a reference group of patients with axSpA without TNFi treatment. Costs for services performed in an outpatient setting, inpatient care, pharmacotherapy and for productivity loss due to absence from paid work were analyzed over a 2-year period. In patients treated with TNFi , the 2‑year period included 1 year before and 1 year after the initiation of TNFi. RESULTS: Data from 1455 axSpA patients who received TNFi treatment were included in the analyses. Costs for services performed in an outpatient setting, inpatient care, pharmacotherapy (excluding TNFi) as well as productivity loss significantly decreased after initiation of TNFi. Mean total costs increased from € 6075 in the year prior to TNFi initiation to € 27,871 in the year after TNFi initiation. Excluding costs for TNFi, total costs decreased by 22% to € 4761. Mean total costs among the reference group of 1455 age and sex-matched axSpA patients who did not receive TNFi remained stable over 2 years: € 3939 in the first year vs. € 3832 in the second year. CONCLUSION: Initiation of TNFi treatment led to a sharp increase in the total costs of axSpA patients. Part of this increase was offset by a decrease of costs for services performed in an outpatient setting, inpatient care, pharmacotherapy (excluding TNFi) as well as productivity loss. In patients who did not receive TNFi, the costs remained stable over 2 years.
Entities:
Keywords:
Axial spondylarthritis; Cost of illness; Health care; Health insurance data; Pharmacological treatment
Authors: Dominique Baeten; Joachim Sieper; Jürgen Braun; Xenofon Baraliakos; Maxime Dougados; Paul Emery; Atul Deodhar; Brian Porter; Ruvie Martin; Mats Andersson; Shephard Mpofu; Hanno B Richards Journal: N Engl J Med Date: 2015-12-24 Impact factor: 91.245
Authors: H Haibel; I Redeker; A Zink; J Callhoff; U Marschall; F Hoffmann; J Sieper; D Poddubnyy Journal: Z Rheumatol Date: 2019-11 Impact factor: 1.372
Authors: J C Davis; D M van der Heijde; J Braun; M Dougados; D O Clegg; A J Kivitz; R M Fleischmann; R D Inman; L Ni; S-L Lin; W H Tsuji Journal: Ann Rheum Dis Date: 2007-10-29 Impact factor: 19.103
Authors: Frank Heldmann; Xenofon Baraliakos; Uta Kiltz; Jan Brandt; Irene E van der Horst-Bruinsma; Robert Landewé; Joachim Sieper; Gerd Rüdiger Burmester; Filip van den Bosch; Kurt de Vlam; Hill Gaston; Mathias Gruenke; Matthias Witt; Thierry Appelboom; Paul Emery; Maxime Dougados; Marjatta Leirisalo-Repo; Maxime Breban; Juergen Braun Journal: Clin Exp Rheumatol Date: 2016-03-25 Impact factor: 4.473
Authors: Désirée M van der Heijde; Dennis A Revicki; Katherine L Gooch; Robert L Wong; Hartmut Kupper; Neesha Harnam; Chris Thompson; Joachim Sieper Journal: Arthritis Res Ther Date: 2009-08-17 Impact factor: 5.156
Authors: Johanna Callhoff; Hannes Jacobs; Katinka Albrecht; Joachim Saam; Angela Zink; Falk Hoffmann Journal: Int J Environ Res Public Health Date: 2020-12-09 Impact factor: 3.390